Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Retinoblastoma
100%
Enucleation
35%
Visual Acuity
26%
Chemotherapy
25%
Orbital Cellulitis
24%
Treatment Outcome
22%
Recurrent Disease
21%
Diseases
20%
Bevacizumab
20%
Triamcinolone Acetonide
20%
Lung Tuberculosis
20%
Scleromalacia
20%
Matrix Metalloproteinase
20%
Penetrating Trauma
20%
Mucormycosis
20%
Ptosis (Eyelid)
20%
Orbital Inflammation
20%
Tolosa-Hunt Syndrome
20%
Disease Course
20%
Neoplasm
20%
Fistula
20%
Carotid-Cavernous Fistula
20%
Arteriovenous Malformation
20%
Corticosteroid
16%
Extended Spectrum Beta Lactamase
15%
Bacterium
15%
Metalloprotease Inhibitor
13%
Gelatinase A
13%
Low and Middle Income Countries
11%
Exophthalmos
11%
Inflammatory Disorder
10%
Penicillinase
10%
Systemic Autoimmune Disease
10%
Tuberculosis
10%
Ptosis
10%
Early Diagnosis
9%
Abscess
9%
Eye Movement
9%
X-Ray Computed Tomography
9%
Intraarterial Drug Administration
8%
Drug Megadose
8%
Methotrexate
8%
Differential Diagnosis
8%
Cranial Nerve Paralysis
8%
Treatment Group
6%
Visual Impairment
6%
Hazard Ratio
6%
Case Presentation
6%
Patient Referral
6%
Pus
5%
Keyphrases
Intravitreal Triamcinolone Acetonide
26%
Retinoblastoma
20%
Bevacizumab
20%
Injury Model
20%
Tumor Necrosis Factor-α
20%
Interleukin-10
20%
Anti-inflammatory Effect
20%
Eye Health
20%
Keratitis
20%
Epigallocatechin Gallate
20%
Pseudomonas Aeruginosa (P. aeruginosa)
20%
Penetrating Injury
20%
Europe
20%
Challenge Course
20%
Wyburn-Mason Syndrome
20%
Dural Carotid Cavernous Fistula
20%
Clinical Course
20%
Cross-sectional multicentre Study
20%
Matrix metalloproteinase-2 (MMP-2)
20%
Diagnostic Challenges
20%
Arteriovenous Malformation
20%
Non-visualization
20%
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
13%
Left Eye
11%
Enucleation
10%
Middle-income Countries
10%
Corneal Perforation
10%
Intravenous Chemotherapy
10%
Intra-arterial Chemotherapy
10%
Intraocular Tumor
10%
Retina
7%
Treatment Group
6%
Exoneration
6%
Statistical Analysis
6%
Bevacizumab Therapy
5%
High-income Countries
5%
Laterality
5%
Inflammatory Process
5%
Anti-inflammatory Properties
5%
NF-B
5%
By Stages
5%
Wound Healing Process
5%
Myogenic Mechanism
5%
Overcorrection
5%
Scar
5%
Economic Factors
5%
M2 Macrophages
5%
Camellia Sinensis
5%
Polyphenols
5%
Economic Status
5%
Pharmacology, Toxicology and Pharmaceutical Science
Triamcinolone Acetonide
60%
Bevacizumab
60%
Plasminogen Activator Inhibitor 1
27%
Vitreoretinopathy
25%
Tumor Necrosis Factor
24%
Interleukin 10
24%
Leporidae
22%
Wound Healing
20%
Antiinflammatory Activity
20%
Keratitis
20%
Pseudomonas aeruginosa
20%
Epigallocatechin Gallate
20%
Penetrating Trauma
20%
Matrix Metalloproteinase
20%
Transforming Growth Factor Beta
20%
Vasculotropin
18%
Inflammation
17%
Fibrosis
15%
Treatment Group
15%
Gelatinase A
13%
Tissue Inhibitor of Metalloproteinase
13%
Wound
10%
Anti-Inflammatory Drug
10%
Cancer Growth Factor
8%
Corticosteroid
6%
Experimental Rabbit
6%
New Zealand Rabbit
6%
Rabbit Model
6%
Eye Injury
5%
Antioxidant
5%
Cornea Injury
5%
Cornea Perforation
5%
Camellia Sinensis
5%
Scar Formation
5%
Polyphenol
5%
Bacterium
5%
Antimicrobial Agent
5%
